Background: Phase III randomized clinical trials (RCTs) have become larger and are powered to detect small absolute benefits. Temporal changes in absolute benefits of experimental medical therapies reported in RCTs are unknown.
medical therapies for metastatic breast and colorectal cancer and levels of endorsement of new medical therapies by health professionals. methods search strategy and study selection
We searched Medline databases in June 2008 to identify all large RCTs with ‡200 participants, published in English from 1975 to 2007, which evaluated medical therapies for the treatment of breast or colorectal cancer (including colon or rectum site-specific trials). We used a cut-off of ‡200 participants as an inclusion criterion for RCTs to decrease the probability of including RCTs with false-positive or false-negative results. We chose breast and colorectal cancer because the largest number of medical therapies has been approved for these types of solid tumors [9] , implying a large number of published phase III clinical trials. We used the MeSH search terms 'breast neoplasms', 'colonic neoplasms', 'colorectal neoplasms' and 'rectal neoplasms' and the keywords 'phase III trial' and 'randomized trial'. The results were then manually filtered and ineligible trials were excluded according to the following criteria: sample size <200 participants, phase I/pilot or phase II trials, multiple reports of the same trial (the first final report was used), trials evaluating surgery or radiation therapy, trials of screening and prevention (including prevention of side-effects), trials evaluating the same therapy at different doses, review articles, equivalence studies and trials with no time-to-event end points.
data extraction and analysis
Our search strategy included 161 papers from high impact journals, identified in an earlier study by our group [6] , as well as new articles. For newly identified RCTs, a data extraction form was designed to capture information from the report and was divided into the following sections: methodology, sponsorship, results, study conclusion (by study author and by our independent assessment) and monthly incremental costs of the Food and Drug Administration (FDA)-approved therapy if used for treatment of metastatic disease. A data key was used to ensure consistency. Much of the methodology and sponsorship data had been collected for RCTs from the papers included in the study by Booth et al. [6] and a modified version of the extraction form was used for them. The forms were piloted on 10 new RCTs trials and 10 from the existing database, and modified as necessary.
To assign sponsorship, studies were classified as for-profit, not-for-profit, mixed or with unknown sources of funding [6, [10] [11] [12] . The study author's interpretation (i.e. authors' score) and our independent conclusions (reviewer's score) were each based upon a previously reported 7-point ordinal scale previously designed to assess statistical significance and magnitude of effect [6, 11] .
Absolute differences in primary and secondary time-to-event end points between experimental and control treatment arms were extracted: these end points were either on the basis of explicit statements in the articles or were those implied to be of primary and secondary importance. Time-to-event end points were classified either as OS or others, which included event-free survival (EFS), disease-free survival (DFS) and relapse-free survival (RFS) for RCTs evaluating adjuvant treatment and time to progression, progression-free survival (PFS) and time to treatment failure for RCTs evaluating treatments of metastatic disease.
Absolute benefits of experimental treatments were determined as (i) the absolute difference between experimental and control treatment arms at an individual point on the x-axis (time) for adjuvant RCTs (e.g. 5-year OS or 3-year DFS) or on the y-axis for metastatic RCTs (e.g. median OS or PFS) as per usual practice (i.e. usual method; Figure 1A and B) and (ii) the area between the curves of experimental and control arms up to a predefined time (i.e. area method; Figure 1C ). The predefined time points are presented in Tables 3 and 4. The area between time-to-event curves was determined for those RCTs, which presented such data graphically. The area under each curve was determined by capturing the data points of a given curve using UN-SCAN-ITä Graph Digitizing Software (Silk Scientific Inc., Orem, Utah). The difference in area between the two curves up to the predetermined time was always calculated as experimental arm minus the control arm. Due to differences in the size and scales of figures presenting time-to-event curves in different RCTs, the area between the curves up to a certain time was calculated as a percentage of the area for the entire graph up to the same time ( Figure 1C) ; this adjustment enabled comparison of absolute benefits determined by the area method between different RCTs. Furthermore, dividing the area between curves by the whole graph area is analogous to the assessment of absolute benefit by the standard method while estimates determined by both methods do not depend on the outcome in the control arm. In RCTs with more than two treatment arms, analysis was on the basis of the experimental arm with the largest absolute benefit.
We calculated the incremental monthly cost of new medical therapies evaluated in RCTs for metastatic cancer published from 1995 to 2007, which contributed to approval of the experimental treatment by the FDA. The trial was classified as having contributed to FDA approval if it was explicitly cited in the label [13] . Trials for metastatic disease were used exclusively because most oncology drugs are initially approved in this setting. Time restraints were applied due to the substantial change in the cost of a drug that occurs after its patent has expired. Incremental costs were calculated compared with the control arm, which was usually the existing standard of care.
All data were entered into a spreadsheet using Microsoft Excel. To assess interobserver variability, two authors (BS and PCH) independently assessed a random sample of 20 RCTs and the results were compared.
statistical analysis
Descriptive statistics were used to describe time-to-event end points and to summarize results for each of the time periods: 1975-1985, 1986-1995 and 1996-2007 . Among trials for breast and colorectal cancer, RCTs were further categorized as adjuvant/neoadjuvant (hereafter adjuvant) or metastatic; the latter was further subcategorized as first-line and greater than or equal to second-line metastatic RCTs. Absolute benefits in time-toevent end points were described for each time period by the usual singlepoint method and by the area method. The Cochran-Armitage test, Jonckheere-Terpstra test and Kendall statistics were used to analyze trends over the three time periods for binary, multilevel and continuous outcomes, respectively. All analysis was carried out in SAS v9.1 (SAS Institute, Cary, NC). P values are given without correction for multiple testing.
results

search results
Our original search yielded 946 articles, of which 710 were excluded for the following reasons: sample size <200 (n = 259); phase I, phase II or pilot studies (n = 21); multiple reports of the same trials (n = 99); trials evaluating surgical or radiation therapies (n = 55); trials evaluating screening or prevention techniques (n = 110); trials evaluating the same therapy at different doses (n = 69); review articles (n = 88); equivalence studies (n = 6) and trials with no time-to-event end points (n = 3). This left a final sample of 236 trials, including 161 from the existing database and 75 new trials. Interobserver agreement between the two data abstractors (on the basis of independent data extraction from 20 studies) was found to be very good: kappa = 0.84 and kappa = 0.86 for reviewer and author's scores, respectively.
original article Annals of Oncology
characteristics of RCTs
For breast cancer, there were 102 trials evaluating adjuvant treatment and 66 trials for metastatic disease; there were 33 adjuvant trials and 35 trials for metastatic colorectal cancer (Table 1) .
There was a substantial increase in the number of RCTs evaluating experimental medical therapies for breast and colorectal cancer in both the adjuvant and metastatic setting over the three time periods (P < 0.01). Over time, RCTs in breast and colorectal cancer became larger and more likely to be multicenter and international in scope. Contemporary trials were significantly more likely to be funded by industry and also more likely to have used an active agent/treatment in the control arm (Table 1 ). In 56 (24%) RCTs, the control arm was compared with more than one experimental treatment arm. Our analysis of trend included 452 primary and secondary time-to-event end points; 259 from RCTs evaluating adjuvant treatment and 193 from RCTs for metastatic disease.
Overall, the strength of endorsement of the experimental arm did not change over time from the perspective of authors of the articles or reviewers. Median author's scores and proportion of RCTs in which authors strongly endorsed experimental therapies were significantly higher for authors as compared with reviewers (P < 0.001). In RCTs evaluating treatment of metastatic disease, the strength of author's endorsement and proportion of RCTs in which authors strongly endorsed the experimental medical therapies increased significantly over time (P = 0.006). For trials evaluating adjuvant treatments, there was no change in the strength of author's endorsement and a trend for a decrease in the proportion of RCTs in which authors strongly endorsed the experimental medical therapy over time (P = 0.03) ( Table 1) .
baseline risk of participants and outcome in control arms of RCTs
In RCTs evaluating adjuvant treatment of breast cancer, the proportion of participants with primary breast cancers that had a more favorable prognosis increased over time (Table 2) . Information on characteristics of primary colorectal tumors was often missing. In RCTs evaluating adjuvant treatment, there was a consistent trend to improvement in the outcome in Figure 1 . Schematic presentation of assessment of absolute differences between arms in phase III clinical trials. Absolute differences between curves are determined by two methods: (i) at one point (usual method; A and B) and as (ii) the area between curves up to a predefined time point (area method; C). The area between curves expressed as a percentage of the area of the whole graph enables comparison of absolute differences between different randomized clinical trials. control arms over time (Table 2) . Outcome in control arms of RCTs evaluating treatment of metastatic disease did not change over time (data not shown).
absolute benefits of experimental medical therapies in adjuvant RCTs
In adjuvant RCTs for breast cancer, median absolute benefits in 3-year EFS, DFS or RFS measured by the usual single-point method decreased significantly across the three study periods (9.5% versus 10% versus 3%; P < 0.001). Analysis by the area method up to 3 years corroborated this observation (9.5% versus 4.5% versus 2.2%; P < 0.001). Median absolute improvement in 5-year OS due to experimental medical therapies was already small during the first time period (2.5%-3%) and did not change significantly (1.3%-2% in the last time period) ( Table 3) . In two RCTs for breast cancer and one RCT for colorectal cancer, the appropriate line of treatment of metastatic disease could not be categorized. b Study conclusions were assigned a score 4 of 7 for a neutral statement, 7 of 7 for strong endorsement of the experimental arm and 1 of 7 for strong endorsement of the control arm. Scores 5 and 6 represent increasing endorsement of experimental therapy and 3 and 2 increasing endorsement of the control arm [11] . RCTs, randomized clinical trials.
original article
Annals of Oncology
There were substantially fewer RCTs of adjuvant therapy for colorectal cancer as compared with breast cancer (33 versus 102). Median absolute benefits in 3-year EFS, DFS or RFS and in 5-year OS did not change significantly over time when measured by the usual single-point method. However, analysis by the area method demonstrated a trend of decreasing median absolute benefits in time-to-event end points up to 3 years (6.7% versus 5.8% versus 2.7%; P = 0.20) and for OS up to 5 years (6.8% versus 4.1% versus 1.9%; P = 0.04) ( Table 3 ).
When we analyzed only statistically significant (i.e. P £ 0.05) absolute differences between experimental and control treatment arms in RCTs evaluating adjuvant treatment of breast cancer, we observed a similar trend of decreasing median absolute benefits in 3-year EFS, DFS and RFS over time (12.5% versus 13% versus 5%; P < 0.001 by the single-point method and 10.3% versus 7.4% versus 3%; P < 0.001 by the area method). Similar analysis for adjuvant RCTs of colorectal cancer was not feasible due to the small number of RCTs with statistically significant results. n.s., not significant (P > 0.05). RCTs, randomized clinical trials; T, tumor; ER, estrogen receptor; EFS, event-free survival; DFS, disease-free survival; RFS, relapse-free survival; OS, overall survival; NA, not applicable. No significant changes in median absolute benefit occurred over time in time-to-event end points for RCTs in the first-line setting for breast and colorectal cancer, whether measured as per usual practice or by the area method. For RCTs evaluating ‡second-line treatment, there was a trend to increasing median absolute benefits over time. However, there were only six RCTs for both breast and colorectal cancer in the first two decades and this result should be interpreted cautiously (Table 4) .
changes in incremental costs of new medical therapies
In the period 1995-2007, we found 24 RCTs that were mentioned explicitly in the labels of approved drugs. There was a large increase in monthly incremental costs of medical therapies approved for metastatic breast and colorectal cancer (1995: median $64; 2007: median $6559; P < 0.0001) ( Table 5 ).
discussion
Phase III trials for breast and colorectal cancer have become larger with time (Table 1) and therefore have potential to detect smaller absolute benefits. We found that absolute benefits of experimental medical therapies in RCTs evaluating adjuvant therapy for these two cancers decreased substantially, whether described by a single-point estimate or by the area between time-to-event curves; they were in the range of only 1.3%-2.7% when measured by the area method in the most recent time period (1996-2007; Table 3 ). The decreasing absolute benefit from new adjuvant treatments is probably due in part to improved outcome in the control arms of the RCTs, associated with enrollment of patients with more favorable primary tumors and/or the use of active and more effective therapies in the control arms (Table 2 ). In contrast, we observed no significant change in outcome in the control arms or in absolute benefits of experimental therapies in RCTs evaluating treatment of metastatic disease. A dramatic increase in the cost of new treatments of metastatic colorectal cancer has been reported previously [14, 15] . Here, we found that the monthly incremental costs of approved experimental medical therapies for metastatic breast and colorectal cancer increased 100-fold, without increase in the absolute benefit gained. Thus, new therapies in the incurable settings of metastatic breast and colorectal cancer are becoming much less cost-effective. Moreover, absolute benefits of new therapies evaluated in RCTs, which often include a highly selected population of patients, might not be replicated at the population level [16] . Comorbidity is an independent prognostic factor in patients with cancer, and extrapolation of results seen in patients with better performance status to those with worse performance status may lead to loss of benefit or even harm from a new treatment [17, 18] .
Our analysis showed that endorsement of experimental medical therapies by authors in adjuvant RCTs did not change significantly over time, despite decreasing absolute benefits in adjuvant RCTs. However, there was a trend to a decrease in the number of adjuvant RCTs, in which experimental medical therapies were strongly endorsed by authors. In contrast, in RCTs evaluating treatment of metastatic disease, author's endorsement of experimental therapies increased significantly The strength of our analysis is in demonstration of decreasing absolute benefits of experimental medical therapies in RCTs by two methods. As compared with the usual singlepoint method for describing absolute benefit, the area method may be advantageous: it includes all data on time-to-event end points up to a predefined time and remains relevant when survival curves do not satisfy proportional hazards and/or have unusual shapes. Results generated in a subanalysis of RCTs for breast cancer with statistically significant results also demonstrated a trend of decreasing absolute benefits. Absolute differences between treatment arms can be affected by censoring, which accumulates with longer follow-up. We tried to avoid the effect of censoring by measurement of absolute benefits at relatively early time points.
Our analysis included RCTs for breast and colorectal cancer only and cannot be generalized to other cancer sites. Our choice of RCTs with a minimal accrual of 200 patients was arbitrary, but smaller trials have a higher probability of false-positive and false-negative results; despite variability in the sample size of the RCTs, our estimates of absolute benefit derived from each RCT have been assigned the same weight in the summary results. A separate analysis of trend in absolute benefits in RCTs without an active treatment in the control arm was not feasible due to a small number of RCTs in all three decades (11 versus 29 versus 29).
In conclusion, experimental medical therapies in RCTs evaluating adjuvant treatment of breast and colorectal cancer show decreasing absolute benefits but they are more often compared with an active treatment in the control arm and tested in a population of patients with a more favorable cancer. New and expensive treatments of metastatic disease show unchanging levels of benefit at rapidly escalating cost. New therapies may not assure meaningful clinical benefit and costeffectiveness. 
